These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 598949)

  • 1. The effect of oral spironolactone and intravenous canrenoate-K on the digoxin radioimmunoassay.
    Lichey J; Schröder R; Rietbrock N
    Int J Clin Pharmacol Biopharm; 1977 Dec; 15(12):557-9. PubMed ID: 598949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma digoxin radioimmunoassay in patients treated with potassium canrenoate and spironolactone. A comparison of two commerical kits.
    Cristodorescu R; Gavrilescu S; Deutsch G; Berger E
    Agressologie; 1978; 19(6):409-14. PubMed ID: 751526
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
    Dasgupta A; Tso G; Wells A
    Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Plasma-digoxin concentration in patients at time of hospital admission (author's transl)].
    Lichey J; Schröder R; Rietbrock N
    Dtsch Med Wochenschr; 1977 Jul; 102(29):1056-60. PubMed ID: 891379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of intravenous canrenoate on the determination of digoxin in serum by radio- and enzyme-immunoassay.
    Lichey J; Rietbrock N; Borner K
    Int J Clin Pharmacol Biopharm; 1979 Feb; 17(2):61-3. PubMed ID: 370036
    [No Abstract]   [Full Text] [Related]  

  • 6. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.
    DeFrance A; Armbruster D; Petty D; Cooper KC; Dasgupta A
    Ther Drug Monit; 2011 Feb; 33(1):128-31. PubMed ID: 21079546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spironolactone interference with digoxin radioimmunoassay in cirrhotic patients.
    DiPiro JT; Cote JR; DiPiro CR; Bustrack JA
    Am J Hosp Pharm; 1980 Nov; 37(11):1518-21. PubMed ID: 7211855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of spironolactone and canrenone on the digoxin radioimmunoassay.
    Huffman DH
    Res Commun Chem Pathol Pharmacol; 1974 Dec; 9(4):787-90. PubMed ID: 4477402
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of canrenoate-K and cardiac glycosides on their tissue distribution and elimination.
    Kuhlmann J; Kötter V; Vöhringer HF; Rietbrock N; Schröder R
    Arzneimittelforschung; 1977 Jul; 27(7):1505-9. PubMed ID: 578485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study of the efficacy of oral potassium canrenoate and spironolactone in essential arterial hypertension].
    Tosti-Croce C; Mantellini R; Fanti P; Sciarra F
    Minerva Med; 1983 Apr; 74(14-15):791-7. PubMed ID: 6339999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new turbidometric digoxin immunoassay on the ADVIA 1650 analyzer is free from interference by spironolactone, potassium canrenoate, and their common metabolite canrenone.
    Datta P; Dasgupta A
    Ther Drug Monit; 2003 Aug; 25(4):478-82. PubMed ID: 12883233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bidirectional (positive/negative) interference of spironolactone, canrenone, and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin.
    Dasgupta A; Saffer H; Wells A; Datta P
    J Clin Lab Anal; 2002; 16(4):172-7. PubMed ID: 12112389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative clinical study of spironolactone and potassium canrenoate. A randomized evaluation with double cross-over.
    Emili M; Cuppone R; Ricci GL
    Arzneimittelforschung; 1988 Oct; 38(10):1492-5. PubMed ID: 3058132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.
    Dasgupta A; Johnson MJ; Sengupta TK
    J Clin Lab Anal; 2012 May; 26(3):143-7. PubMed ID: 22628228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canrenoate--a spironolactone metabolite. Acute cardiac effects in digitalized patients.
    Waldorff S; Buch J
    Eur J Cardiol; 1979 Aug; 10(2):143-9. PubMed ID: 477703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.
    Dasgupta A; Johnson MJ
    J Clin Lab Anal; 2010; 24(6):413-7. PubMed ID: 21089173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spirolactones: clinical and pharmacologic studies.
    Corvol P; Claire M; Rafestin-Oblin ME; Michaud A; Roth-Meyer C; Menard J
    Adv Nephrol Necker Hosp; 1977; 7():199-215. PubMed ID: 208407
    [No Abstract]   [Full Text] [Related]  

  • 18. A new enzyme-linked chemiluminescent immunosorbent digoxin assay is virtually free from interference of spironolactone, potassium canrenoate, and their common metabolite canrenone.
    Dasgupta A; Kang E; Datta P
    J Clin Lab Anal; 2006; 20(5):204-8. PubMed ID: 16960898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium-activated adenosine triphosphatase.
    Finotti P; Palatini P
    J Pharmacol Exp Ther; 1981 Jun; 217(3):784-90. PubMed ID: 6262496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spironolactone and canrenoate-K: relative potency at steady state.
    Ramsay L; Asbury M; Shelton J; Harrison I
    Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.